[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561720":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":29,"collaborators":25,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":25,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":25,"overallStatus":53,"whyStopped":25,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":25},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","EXPERIMENTAL","bacillus coagulans combined with the best treatment options for preventing aGVHD",[13],"Drug: bacillus coagulans combined with the best treatment options for preventing aGVHD",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","ACTIVE_COMPARATOR","The best treatment options for preventing aGVHD",[19],"Drug: BAT",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","BAT means the best treatment options for preventing aGVHD",[9],null,{"type":22,"name":27,"description":27,"armGroupLabels":28,"otherNames":25},"BAT",[15],{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Yamin Fan","Principal Investigator","100561720","a-clinical-study-of-bacillus-coagulans-in-acute-graft-versus-host-disease-after-hematopoietic-stem-cell-transplantation-100561720",false,"NCT06593834","A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation","A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease (aGVHD) After Hematopoietic Stem Cell Transplantation","aGVHD；BAT","Inclusion Criteria:\n\n1. Patients are fully aware of the study, voluntarily participate and sign informed consent;\n2. Age: ≥18 years old;\n3. Patients with hematologic malignancies undergoing allo-HSCT and patients with severe aplastic anemia (SAA) undergoing allo-HSCT were treated with myeloablative conditioning (MAC).\n\nExclusion Criteria:\n\n1. Refused to participate in this clinical study;\n2. Unable to take the drug orally;\n3. Allergic to Bacillus coagulans;\n4. People take allo-HSCT with reduced intensity conditioning (RIC) and nonmyeloablative conditioning (NMC);lymphoma or multiple myeloma with auto-HSCT; multiple myeloma patients.","ALL","18 Years","80 Years",{"count":45,"type":46},286,"ESTIMATED","INTERVENTIONAL",[49],"NA","To evaluate the preventive effect of Bacillus coagulans on acute graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation",[52],"Acute Graft-versus-host Disease","NOT_YET_RECRUITING","2024-09-22",{"date":56,"type":57},"2024-09-25","ACTUAL",{"date":59,"type":46},"2024-09-27",{"date":61,"type":46},"2026-04-30",{"name":31,"class":6}]